{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:28:15Z","timestamp":1792859295081,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03212-5","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:05:31Z","timestamp":1724483131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-na\u00efve EGFR-mutated NSCLC based on performance status"],"prefix":"10.1186","volume":"24","author":[{"given":"Yoshihiko","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Isa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Mizumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Nakatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Kuwako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhisa","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"3212_CR1","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985\u201393. https:\/\/doi.org\/10.18632\/oncotarget.12587.","journal-title":"Oncotarget"},{"key":"3212_CR2","doi-asserted-by":"publisher","first-page":"CD010383","DOI":"10.1002\/14651858.CD010383.pub2","volume":"3","author":"J Greenhalgh","year":"2021","unstructured":"Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021;3:CD010383. https:\/\/doi.org\/10.1002\/14651858.CD010383.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"3212_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.lungcan.2018.10.027","volume":"376","author":"TS Mok","year":"2016","unstructured":"Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2016;376:629\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.027.","journal-title":"N Engl J Med"},{"key":"3212_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2017","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2017;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"3212_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"key":"3212_CR6","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.21037\/jtd.2019.06.03","volume":"11","author":"Y Kato","year":"2019","unstructured":"Kato Y, Hosomi Y, Watanabe K, et al. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2019;11:2350\u201360. https:\/\/doi.org\/10.21037\/jtd.2019.06.03.","journal-title":"J Thorac Dis"},{"key":"3212_CR7","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s10637-020-00943-0","volume":"38","author":"K Nakashima","year":"2020","unstructured":"Nakashima K, Ozawa Y, Daga H, et al. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Invest New Drugs. 2020;38:1854\u201361. https:\/\/doi.org\/10.1007\/s10637-020-00943-0.","journal-title":"Invest New Drugs"},{"key":"3212_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10147-021-02043-2","volume":"27","author":"Y Tsubata","year":"2022","unstructured":"Tsubata Y, Watanabe K, Saito R, et al. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2022;27:112\u201320. https:\/\/doi.org\/10.1007\/s10147-021-02043-2.","journal-title":"Int J Clin Oncol"},{"key":"3212_CR9","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1111\/1759-7714.14608","volume":"13","author":"S Teranishi","year":"2022","unstructured":"Teranishi S, Sugimoto C, Nagaoka S, et al. Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thorac Cancer. 2022;13:2741\u201350. https:\/\/doi.org\/10.1111\/1759-7714.14608.","journal-title":"Thorac Cancer"},{"key":"3212_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10637-021-01195-2","volume":"40","author":"S Igawa","year":"2022","unstructured":"Igawa S, Fukui T, Kasajima M, et al. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: a prospective observational study. Invest New Drugs. 2022;40:430\u20137. https:\/\/doi.org\/10.1007\/s10637-021-01195-2.","journal-title":"Invest New Drugs"},{"key":"3212_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/fon-2021-0947","volume":"18","author":"S Takamizawa","year":"2022","unstructured":"Takamizawa S, Okuma Y, Kato Y, Hakozaki T, Kitagawa S, Zenke Y. First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. Future Oncol. 2022;18:291\u2013300. https:\/\/doi.org\/10.2217\/fon-2021-0947.","journal-title":"Future Oncol"},{"key":"3212_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","volume":"19","author":"P Stockhammer","year":"2024","unstructured":"Stockhammer P, Grant M, Wurtz A, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J Thorac Oncol. 2024;19:240\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2023.10.001.","journal-title":"J Thorac Oncol"},{"key":"3212_CR13","doi-asserted-by":"publisher","first-page":"101580","DOI":"10.1016\/j.esmoop.2023.101580","volume":"8","author":"EB Garon","year":"2023","unstructured":"Garon EB, Reck M, Nishio K, et al. Ramucirumab plus Erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open. 2023;8:101580. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101580.","journal-title":"ESMO Open"},{"key":"3212_CR14","doi-asserted-by":"publisher","unstructured":"Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990:61:759\u2013767. https:\/\/doi.org\/10.1016\/0092-8674(90)90186-i","DOI":"10.1016\/0092-8674(90)90186-i"},{"key":"3212_CR15","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s00018-019-03052-1","volume":"76","author":"Z Szvicsek","year":"2019","unstructured":"Szvicsek Z, Oszvald A, Szabo L, et al. Extracellular vesicle release from intestinal organoids is modulated by apc mutation and other colorectal cancer progression factors. Cell Mol Life Sci. 2019;76:2463\u201376. https:\/\/doi.org\/10.1007\/s00018-019-03052-1.","journal-title":"Cell Mol Life Sci"},{"key":"3212_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/1759-7714.12450","volume":"8","author":"B Hu","year":"2017","unstructured":"Hu B, Zhang H, Wei H, et al. Does adenomatous polyposis coli gene promoter 1A methylation increase non-small cell lung cancer risk? A meta-analysis. Thorac Cancer. 2017;8:410\u20136. https:\/\/doi.org\/10.1111\/1759-7714.12450.","journal-title":"Thorac Cancer"},{"key":"3212_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759\u201367. https:\/\/doi.org\/10.1016\/0092-8674(90)90186-I.","journal-title":"Cell"},{"key":"3212_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.1848370","volume":"251","author":"KW Kinzler","year":"1991","unstructured":"Kinzler KW, Vogelstein B, Herrup K, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 1991;251:1366\u201370. https:\/\/doi.org\/10.1126\/science.1848370.","journal-title":"Science"},{"key":"3212_CR19","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/hmg\/10.26.3001","volume":"10","author":"M Esteller","year":"2001","unstructured":"Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10:3001\u20137. https:\/\/doi.org\/10.1093\/hmg\/10.26.3001.","journal-title":"Hum Mol Genet"},{"key":"3212_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495\u2013509. https:\/\/doi.org\/10.1038\/s41568-019-0179-8.","journal-title":"Nat Rev Cancer"},{"key":"3212_CR21","doi-asserted-by":"publisher","first-page":"107249","DOI":"10.1016\/j.lungcan.2023.107249","volume":"181","author":"F Pezzuto","year":"2023","unstructured":"Pezzuto F, Hofman V, Bontoux C, et al. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: optimizing the efficacy of targeted therapies? Lung Cancer. 2023;181:107249. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107249.","journal-title":"Lung Cancer"},{"key":"3212_CR22","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1200\/JCO.2005.02.7347","volume":"23","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride and carboplatin\/paclitaxel in advanced non\u2013small-cell lung cancer. J Clin Oncol. 2008;23:5892\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.02.7347.","journal-title":"J Clin Oncol"},{"key":"3212_CR23","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2005","unstructured":"Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2005;101:13306\u201311. https:\/\/doi.org\/10.1073\/pnas.0405220101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3212_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jtho.2018.12.013","volume":"14","author":"ZY Dong","year":"2019","unstructured":"Dong ZY, Zhong WZ, Zhang XC, et al. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. J Thorac Oncol. 2019;14:519\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.013.","journal-title":"J Thorac Oncol"},{"key":"3212_CR25","doi-asserted-by":"publisher","first-page":"e0287256","DOI":"10.1371\/journal.pone.0287256","volume":"18","author":"Y Kim","year":"2023","unstructured":"Kim Y, Ahn B, Yoon S, et al. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma. PLoS ONE. 2023;18:e0287256. https:\/\/doi.org\/10.1371\/journal.pone.0287256.","journal-title":"PLoS ONE"},{"key":"3212_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0285.","journal-title":"Cancer Discov"},{"key":"3212_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543\u201350. https:\/\/doi.org\/10.1038\/nature13385.","journal-title":"Nature"},{"key":"3212_CR28","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","volume":"24","author":"HA Yu","year":"2018","unstructured":"Yu HA, Suzawa K, Jordan E, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24:3108\u201318. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2961.","journal-title":"Clin Cancer Res"},{"key":"3212_CR29","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ng.3990","volume":"49","author":"CM Blakely","year":"2017","unstructured":"Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49:1693\u2013704. https:\/\/doi.org\/10.1038\/ng.3990.","journal-title":"Nat Genet"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03212-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T07:05:34Z","timestamp":1724483134000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03212-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3212"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03212-5","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective observational study was registered on December 10, 2018, in the Japanese Register of Clinical Trials (JRCT; Clinical Trial Number: jRCTs031180051). Written informed consent was obtained from all patients before the study began, and the National Hospital Organization Review Board for Clinical Trials approved this protocol prior to the start of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Taniguchi Y has received honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, and MSD. Tamiya A has received honoraria from Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Amgen, Taiho Pharmaceutical, Kyowa Kirin, MSD, Takeda Pharmaceutical, Nihon-Kayaku, Novartis, Thermo Fischer, Amgen, Tsumura, Daiich-Sankyo and Merck BioFarma, and research funding from Daiichi-Sankyo, Beigene, and AstraZeneca. Harada D has received honoraria from Takeda Pharmaceutical, Eli Lilly, Chugai Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Towa Pharmaceutical, and Boehringer Ingelheim. Oki M has received Honoraria from AMCO, AstraZeneca, Canon Medical Systems, Chugai Pharmaceutical, Fujifilm Toyama Chemical, Kaneka Medix, Merit Medical Japan, Novartis Pharma, Olympus and Sanofi, and research funding from AbbVie, AstraZeneca, Chugai Pharmaceutical, Fujifilm Toyama Chemical, GlaxoSmithKline, Janssen Pharmaceutical, MSD, Ono Pharmaceutical, Parxel International, Pfizer, Sanofi. Mori M received honoraria from AstraZeneca, Boehringer Ingelheim, MSD, Eli Lilly, Novartis, Chugai Pharmaceutical, Taiho Pharmaceutical, Kyowa-kirin, Ono Pharmaceutical, Otsuka, Nihon-kayaku, Pfizer, Daiici-Sankyo, Takeda Pharmaceutical, and Shionogi and research funding from Chugai Pharmaceutical, Ono Pharmaceutical, MSD, and Delt-fly. Koh Y has received honoraria from Chugai Pharmaceutical, Guardant Health, Amgen, Takeda Pharmaceutical, and Tosoh Corporation and received consulting or advisory roles from Tosoh Corporation and research funding from Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical, Tosoh Corporation, Daiichi Sankyo, Zeon Corporation, Amgen, and Takeda Pharmaceutical. The other co-authors received no honoraria or research funding.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}